We can't find the internet
Attempting to reconnect
Something went wrong
Hang in there while we get back on track
£520.00
It has never been this cheap. We have no record of a lower price.
£520 today · cheaper than every other day in the last 3 months
The 2023-2028 Outlook for Primary Brain Tumor Diagnosis and Treatments in the United States
We'll watch every seller, every day. One email when your price arrives.
Price History & Forecast
Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.
Last 20 days · 20 data points (no recent data)
Historical
Generating forecast…
NEW HERE?
Amazon shows you one price. We show you all of them.
Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.
WHAT'S ON THIS PAGE
↑ Price chart
when this has been cheap or pricey
when this has been cheap or pricey
↑ Forecast
where the price is heading next
where the price is heading next
↓ Statistics
all-time high & low, recent range
all-time high & low, recent range
↑ Price alert
name your number, we'll email you
name your number, we'll email you
Price Distribution
Price distribution over 20 days • 1 price levels
Price Analysis
Most common price: £520 (20 days, 100.0%)
Price range: £520 - £520
Price levels: 1 different prices over 20 days
Description
This study covers the latent demand outlook for primary brain tumor diagnosis and treatments across the states and cities of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 12,600 cities in the United States. For each city in question, the percent share the city is of its state and of the United States as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and city, latent demand estimates are created for primary brain tumor diagnosis and treatments. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of primary brain tumor diagnosis and treatments as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AstraZeneca, Carestream Health, GE Healthcare, Hitachi Medical, Merck & Company, Pfizer, Philips Healthcare, Shimadzu Corporation, Siemens Healthineers, and Toshiba Medical Systems. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).
Product Specifications
- Format
- paperback
- ASIN
- B0BLQNV9PC
- Category
- Books > Subjects
- Domain
- Amazon UK
- Release Date
- 26 October 2022
- Listed Since
- 10 November 2022
Similar Products You Might Like
99% match
The 2023-2028 Outlook for Primary Brain Tumor Diagnosis and Treatments in India
£515.00
11 Aug 2026
99% match
The 2023-2028 Outlook for Brain Tumor Diagnosis and Treatments in the United States
£520.00
15 Aug 2026
99% match
The 2023-2028 Outlook for Brain Tumor Diagnosis and Treatments in India
£515.00
12 Sep 2026
99% match
The 2023 Report on Primary Brain Tumor Diagnosis and Treatments: World Market Segmentation by City
£795.00
29 Aug 2026
99% match
The 2023-2028 Outlook for Primary Brain Tumor Diagnosis and Treatments in China
£495.00
25 Sep 2026
99% match
The 2023-2028 Outlook for Primary Brain Tumor Diagnosis and Treatments in Japan
£495.00
20 Aug 2026
99% match
The 2023-2028 Outlook for Brain Tumor Diagnosis and Treatments in China
£495.00
14 Aug 2026
99% match
The 2023-2028 Outlook for Brain Tumor Diagnosis and Treatments in Japan
£495.00
11 Aug 2026
98% match
The 2025-2030 World Outlook for Primary Brain Tumor Diagnosis and Treatments
Price unavailable
98% match
The 2023-2028 World Outlook for Brain Tumor Diagnosis and Treatments
Price unavailable
98% match
The 2025-2030 World Outlook for Brain Tumor Diagnosis and Treatments
Price unavailable
98% match
The 2023-2028 Outlook for Primary Brain Tumor Diagnosis and Treatments for US Zip Codes
£490.00
22 Aug 2026
98% match
The 2023-2028 Outlook for Brain Tumor Diagnosis and Treatments for US Zip Codes
£490.00
11 Aug 2026
98% match
The 2023 Report on Cell-Based Brain Tumor Therapeutics: World Market Segmentation by City
£795.00
15 Aug 2026
97% match
The 2023-2028 Outlook for Glioblastoma Multiforme Drugs in India
£515.00
25 Aug 2026
97% match
Primary Brain Tumors in Adults: Advances in Mechanistic Understanding, Evaluation, and Management: Volume 166 (Advances in Cancer Research, Volume 166)
Elsevier
£107.39
05 Sep 2026
97% match
Brain Tumors: Current and Emerging Therapeutic Strategies
IntechOpen
£139.00
02 Oct 2026
97% match
The 2023-2028 Outlook for Non-Small Cell Lung Cancer Therapeutics in the United States
£520.00
30 Sep 2026
97% match
Diagnostic Techniques and Surgical Management of Brain Tumors
IntechOpen
£147.51
02 Oct 2026
97% match
Molecular Considerations and Evolving Surgical Management Issues in the Treatment of Patients with a Brain Tumor
IntechOpen
£130.98
01 Oct 2026
97% match
Brain Tumors: Advancements in Diagnostics and Innovative Therapies
CRC Press
£82.73
12 Sep 2026
97% match
The 2023-2028 Outlook for Pseudotumor Cerebri in India
£515.00
28 Aug 2026
97% match
The 2023-2028 Outlook for Pseudotumor Cerebri in the United States
£520.00
03 Sep 2026
97% match
The 2023-2028 Outlook for Non-Small Cell Lung Cancer Therapeutics in India
£515.00
30 Sep 2026